ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.26
-0.11 (-3.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.37
Open3.37
Bid0.00 x 3000
Ask0.00 x 1800
Day's Range3.24 - 3.40
52 Week Range1.58 - 4.09
Volume2,542,225
Avg. Volume1,127,075
Market Cap513.245M
Beta-0.71
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.32
Trade prices are not sourced from all markets
  • Antares Pharma Inc’s (NASDAQ:ATRS) Earnings Dropped -9.2%, Did Its Industry Show Weakness Too?
    Simply Wall St.17 days ago

    Antares Pharma Inc’s (NASDAQ:ATRS) Earnings Dropped -9.2%, Did Its Industry Show Weakness Too?

    When Antares Pharma Inc (NASDAQ:ATRS) announced its most recent earnings (30 June 2018), I did two things: looked at its past earnings track record, then look at what is happeningRead More...

  • GlobeNewswire24 days ago

    Report: Developing Opportunities within Anthera Pharmaceuticals, NRG Energy, Antares Pharma, El Pollo Loco, Paychex, and Cinedigm — Future Expectations, Projections Moving into 2018

    NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anthera ...

  • GlobeNewswire25 days ago

    Antares Pharma to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Rodman & Renshaw 20th Annual Global Investment Conference, sponsored by H. C. Wainwright & Co. LLC., on Thursday, September 6, 2018 at 3:50 p.m. Eastern Time. Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injection technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Zacks Small Cap Research28 days ago

    ATRS: Epinephrine Pen Ready to Go

    On August 16, 2018 the FDA granted approval of Teva’s (TEVA) epinephrine auto-injector for severe allergies. Both the 0.3 mg and the 0.15 mg (EpiPen Jr) were approved, receiving an AB equivalency rating. Teva did not provide details on timing or price, however, Teva has product ready to distribute and should only take only a short time (after printing up the package inserts) to stock the generic version in the drugstore.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ATRS earnings conference call or presentation 7-Aug-18 12:30pm GMT

    Q2 2018 Antares Pharma Inc Earnings Call

  • Why the FDA's generic EpiPen approval is a big win for a N.J. company
    American City Business Journalslast month

    Why the FDA's generic EpiPen approval is a big win for a N.J. company

    Teva received FDA approval of a generic version of Mylan's EpiPen, but it didn't make the device. Here's who did.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Antares Pharma and Adamis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / August 17, 2018 / Biotech stocks Antares Pharma rose marginally and Adamis Pharmaceuticals was in the red on Thursday after news of Teva receiving FDA approval for its generic version of the EpiPen. Antares Pharma, Inc. shares closed up 4.10% on Thursday with an additional 3.33% in gains in after-hours trading. The company announced yesterday that it's partner Teva Pharmaceutical Industries has had its epinephrine auto injector drug-device combination product for emergency treatment of severe allergic reactions, approved by the Food and Drug Administration.

  • GlobeNewswirelast month

    Antares Pharma Announces FDA Approval of Generic EpiPen Utilizing VIBEX Auto Injector

    EWING, N.J., Aug. 16, 2018-- Antares Pharma, Inc. today announced that the U.S. Food and Drug Administration has approved Teva Pharmaceutical Industries, Ltd.’ s epinephrine auto injector drug-device combination ...

  • SmarterAnalystlast month

    Key FDA Decisions Could Power These 3 Biopharma Stocks

    Today, we list 3 biopharma companies that have FDA events approaching along with positive analyst sentiment. In other words, analysts expect these companies' stock prices to appreciate as they draw closer to their respective catalysts. Let's take a closer look at Kala Pharma (NASDAQ:KALA), TherapeuticsMD (NASDAQ:TXMD), and Antares Pharma (NASDAQ:ATRS). Biotech investor anticipation will be high on Friday, August 24, where Kala's Inveltys will be in the spotlight.

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announced last week that it would be working with Pfizer.

  • Why Nielsen Holdings, Diebold Nixdorf, and Antares Pharma Jumped Today
    Motley Foollast month

    Why Nielsen Holdings, Diebold Nixdorf, and Antares Pharma Jumped Today

    Get the scoop on the latest in M&A land.

  • Business Wire2 months ago

    Robbins Arroyo LLP: Antares Pharma, Inc. (ATRS) Misled Shareholders According to a Class Action

    Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Antares Pharma, Inc. (ATRS) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 21, 2016 and October 12, 2017. Antares, a specialty pharmaceutical company, develops pharmaceutical delivery systems, including needle-free and mini-needle injector systems and transdermal gel technologies. According to the complaint, on December 21, 2016, Antares announced its submission of a New Drug Application ("NDA") for Xyosted to the U.S. Food and Drug Administration ("FDA") and spoke optimistically about the drug's potential.

  • Associated Press2 months ago

    Antares Pharma: 2Q Earnings Snapshot

    On a per-share basis, the Ewing, New Jersey-based company said it had a loss of 3 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    Antares Pharma Reports Second Quarter 2018 Operating and Financial Results

    EWING, N.J., Aug. 07, 2018-- Antares Pharma, Inc. today reported operating and financial results for the second quarter ended June 30, 2018. The Company reported revenue of $14.2 million and a net loss ...

  • ACCESSWIRE2 months ago

    Antares Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Antares Pharma, Inc. (NASDAQ: ATRS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • GlobeNewswire2 months ago

    Antares Pharma Appoints Dr. James Tursi Executive Vice President, Head of Research & Development, Chief Medical Officer

    Antares Pharma, Inc. (ATRS) today announced the appointment of James P. Tursi M.D. to the position of Executive Vice President, Head of Research & Development, Chief Medical Officer effective August 6, 2018.  Dr. Tursi has a diversified corporate background including 15 years of drug development experience within the biotech and pharmaceutical industry. Most recently, Dr. James Tursi was the Chief Medical Officer of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since October 1, 2015.  Prior to Aralez, James served as Chief Medical Officer of Innocoll AG where he was responsible for managing all clinical research and development, medical affairs and safety activities for product candidates and medical devices which utilized a proprietary collagen-based technology.

  • Here's Why Antares Pharma Jumped Today
    Motley Fool2 months ago

    Here's Why Antares Pharma Jumped Today

    A deal with Pfizer has investors smiling, but there's no way to analyze the value to the company.

  • ACCESSWIRE2 months ago

    Biotechnology Stocks Trending on New Developments 2018

    CORAL GABLES, FL / ACCESSWIRE / August 6, 2018 / Earnings season continues to roll on this week as a number of companies report second quarter results. In fact over the last 3 months, the Health Care Select Sector SPDR Fund (XLV) has been climbing back toward its 52 week high. Likewise, both the SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology Index ETF (IBB) have maintained their 2018 uptrend despite periodic consolidation throughout the year.

  • Benzinga2 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Bluebird bio Inc (NASDAQ: BLUE ) stock gained more ...

  • GlobeNewswire2 months ago

    Antares Pharma Enters Into Development Agreement With Pfizer Inc.

    EWING, N.J., Aug. 06, 2018-- Antares Pharma, Inc. today announced that it has entered into an agreement with Pfizer Inc. to develop a combination drug device rescue pen. This rescue pen will utilize the ...

  • GlobeNewswire2 months ago

    Antares Pharma to Report Second Quarter 2018 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its second quarter 2018 financial results and recent operating progress before the market opens on Tuesday, August 7, 2018.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on August 7, 2018 to discuss the results. Interested parties may participate in the conference call by dialing 1-888-254-3590 or 1-323-994-2093 and entering access code 4542618.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Tuesday, August 7, 2018, through 11:30 a.m. ET on Thursday, September 6, 2018 by dialing 1-888-203-1112 or 1-719-457-0820 and entering the access code 4542618.  An audio webcast and archive of the conference call will also be available under the “For Investors” section of the Antares Website at www.antarespharma.com.

  • GlobeNewswire2 months ago

    Consolidated Research: 2018 Summary Expectations for South Jersey Industries, Cedar Realty Trust, Antares Pharma, Q2, Cree, and HCI Group — Fundamental Analysis, Key Performance Indications

    NEW YORK, July 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of South ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ATRS earnings conference call or presentation 8-May-18 12:30pm GMT

    Q1 2018 Antares Pharma Inc Earnings Call

  • ACCESSWIRE3 months ago

    Complimentary Technical Snapshots on Akers Biosciences and Two More Medical Supplies Stocks

    Stock Research Monitor: ATRS and BAX LONDON, UK / ACCESSWIRE / July 5, 2018 / If you want a free Stock Review on AKER sign up now at www.wallstequities.com/registration . On Tuesday, July 03, 2018, US ...

  • Is Antares Pharma Inc’s (NASDAQ:ATRS) Balance Sheet A Threat To Its Future?
    Simply Wall St.3 months ago

    Is Antares Pharma Inc’s (NASDAQ:ATRS) Balance Sheet A Threat To Its Future?

    While small-cap stocks, such as Antares Pharma Inc (NASDAQ:ATRS) with its market cap of US$421.86m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...